ANI Pharmaceuticals vs Phibro Animal Health
ANIP and PAHC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and PAHC compare
ANI Pharmaceuticals and Phibro Animal Health are about the same size, with market caps of $1.6B and $1.4B.
On earnings, Phibro Animal Health is cheaper: it trades at 14.4× trailing earnings, against 14.9× for ANI Pharmaceuticals.
ANI Pharmaceuticals grew revenue faster over the last twelve months (30.9% versus 17.1% for Phibro Animal Health).
ANI Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 11.1% compared with 6.6% at Phibro Animal Health.
Phibro Animal Health pays a dividend yielding 1.4%; ANI Pharmaceuticals does not pay one.
Phibro Animal Health scores higher on the StockData Score (22 against 14 for ANI Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | PAHC |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $1.4B |
| Share price | $69.99 | $34.92 |
| Change, 1 year | −16.7% | −22.6% |
| Change, 5 years | 71.7% | 67.2% |
| Beta (5Y) | 0.65 | −0.07 |
| Employees | 970 | 2,605 |
| StockData Score | ||
| Total score | 14 | 22 (better) |
| Valuation score | 5 | 5 |
| Growth score | 2 | 6 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 14.9× | 14.4× (better) |
| P/S | 1.6× | 0.9× (better) |
| P/B | 2.7× (better) | 3.7× |
| EV/EBITDA | 6.6× | 5.4× (better) |
| P/FCF | 9.3× (better) | 144× |
| PEG | – | 0.32 |
| FCF yield | 10.8% (better) | 0.70% |
| Fair value | $133.72 | $65.12 |
| Margin of safety | 47.7% (better) | 46.4% |
| Growth | ||
| Revenue growth (TTM) | 30.9% (better) | 17.1% |
| Revenue growth, 5Y average | 33.5% (better) | 12.7% |
| Net income growth (TTM) | – | 107% |
| EPS growth (TTM) | – | 104% |
| EPS growth, 5Y average | – | 12.6% |
| Profitability | ||
| Gross margin | 60.4% (better) | 33.8% |
| Operating margin | 15.4% (better) | 12.8% |
| Net margin | 11.1% (better) | 6.6% |
| FCF margin | 17.7% (better) | 0.65% |
| Return on equity | 21.0% | 29.7% (better) |
| Return on invested capital | 21.3% | 24.7% (better) |
| Financial health | ||
| Debt / equity | 0.50 | – |
| Net debt / EBITDA | −0.25 | – |
| Interest coverage | 4.8× (better) | 4.2× |
| Current ratio | 2.91 | 2.96 (better) |
| Altman Z-score | 2.53 | 3.02 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Payout ratio | 0.32% | 19.5% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | 1.4% | – |
| Shareholder yield | 1.4% (better) | 1.4% |
| Ownership | ||
| Held by institutions | 100% | 51.8% |
| Held by insiders | 12.3% | 98.9% |
| Insider net buying, 12 months | −$13.6M (better) | −$23.0M |
| Short interest, % of float | 17.8% | 233% |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- PAHC stock overview
- PAHC income statement
- PAHC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.